All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


A Review on Acute Myeloid Leukaemia

Author(s): Maithri Gundaram

Acute myeloid leukaemia (AML) is a life threatening hematologic malignancy. Despite a well-characterized genetic and molecular landscape, targeted therapies for AML have didn't considerably improve clinical outcomes. Over the past decade, proteasome inhibition has been incontestable to be a good therapeutic strategy in many medicine malignancies. Proteasome inhibitors, like bortezomib and carfilzomib, became mainstays of treatment for myeloma and mantle cell malignant neoplastic disease. In light-weight of this success, there has been a surge of literature exploring each the role of the proteasome and also the effects of proteasome inhibition in acute myeloid leukaemia. Pre-clinical studies have incontestable that proteasome inhibition disrupts proliferative cell sign pathways, exhibits cytotoxic synergism with different chemotherapeutics and induces autophagy of cancer-related proteins. Meanwhile, clinical trials incorporating bortezomib into combination therapy regimens have reported a variety of responses in AML patients, with complete remission rates. In a trial to focus additional investigation into this space, these recent studies and their findings are reviewed here.

Share this       

Select your language of interest to view the total content in your interested language

Table of Contents

Google Scholar citation report
Citations : 17

Biochemistry & Molecular Biology Letters received 17 citations as per Google Scholar report

Indexed In

  • Open J Gate
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)

Read More